These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 19536819)
41. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability. Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639 [TBL] [Abstract][Full Text] [Related]
42. Clinical implications of genetic testing of hereditary nonpolyposis colorectal cancer. Vasen HF; Wijnen J Cytogenet Cell Genet; 1999; 86(2):136-9. PubMed ID: 10545704 [No Abstract] [Full Text] [Related]
49. A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. van Lier MG; Wagner A; van Leerdam ME; Biermann K; Kuipers EJ; Steyerberg EW; Dubbink HJ; Dinjens WN J Cell Mol Med; 2010 Jan; 14(1-2):181-97. PubMed ID: 19929944 [TBL] [Abstract][Full Text] [Related]
50. Identifying Lynch syndrome: we are all responsible. Sanchez JA; Vogel JD; Kalady MF; Bronner MP; Skacel M; Church JM Dis Colon Rectum; 2008 Dec; 51(12):1750-6. PubMed ID: 18682882 [TBL] [Abstract][Full Text] [Related]
51. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Rodríguez-Soler M; Pérez-Carbonell L; Guarinos C; Zapater P; Castillejo A; Barberá VM; Juárez M; Bessa X; Xicola RM; Clofent J; Bujanda L; Balaguer F; Reñé JM; de-Castro L; Marín-Gabriel JC; Lanas A; Cubiella J; Nicolás-Pérez D; Brea-Fernández A; Castellví-Bel S; Alenda C; Ruiz-Ponte C; Carracedo A; Castells A; Andreu M; Llor X; Soto JL; Payá A; Jover R Gastroenterology; 2013 May; 144(5):926-932.e1; quiz e13-4. PubMed ID: 23354017 [TBL] [Abstract][Full Text] [Related]
52. What's new in hereditary colorectal cancer? Jass JR Arch Pathol Lab Med; 2005 Nov; 129(11):1380-4. PubMed ID: 16253015 [TBL] [Abstract][Full Text] [Related]
53. Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. Hampel H J Natl Compr Canc Netw; 2010 May; 8(5):597-601. PubMed ID: 20495086 [TBL] [Abstract][Full Text] [Related]
54. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Boland CR; Koi M; Chang DK; Carethers JM Fam Cancer; 2008; 7(1):41-52. PubMed ID: 17636426 [TBL] [Abstract][Full Text] [Related]
56. A new interphase fluorescence in situ hybridization approach for genomic rearrangements involving MLH1 and MSH6 in hereditary nonpolyposis colorectal cancer-suspected mutation-negative patients. Koehler U; Grabowski M; Bacher U; Holinski-Feder E Cancer Genet Cytogenet; 2007 May; 175(1):81-4. PubMed ID: 17498565 [No Abstract] [Full Text] [Related]